Abstract |
We have analyzed the long-term outcome and toxicities in 98 patients with high-risk acute myelogenous leukemia (AML) who were treated with autologous bone marrow transplantation (ABMT) and monitored for a median observation period of 11.67 years. Between 1983 and 1994, 98 patients in our institution in first or second and higher complete remission (CR) underwent total body irradiation and high-dose cyclophosphamide prior to ABMT purged with mafosfamide. Twenty-seven out of the 90 evaluable patients (30%) were alive and in continuous CR for a median of 11.67 years (range, 6.39-15.53) after ABMT and could be considered as 'cured'. Among the 90 patients, 39 were transplanted at first CR and had a significantly higher survival rate than those transplanted at > or = 2 CR. Younger patients (<40 years) had a better prognosis and patients with FAB M1-4 had a more favorable outcome than those with M5. Long-term complications included four patients with cardiac complications, two with renal insufficiency. Five developed HCV infections, four myelodysplastic syndrome. The incidence of cataract among the long-term survivors was 44.4%. Therefore, a significant number of adult patients with AML in first CR derived long-term benefit from ABMT, despite the risks of a few long-term complications and of MDS (4.4%).
|
Authors | A Abdallah, G Egerer, R M Weber-Nordt, M Körbling, R Haas, A D Ho |
Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 30
Issue 1
Pg. 15-22
(Jul 2002)
ISSN: 0268-3369 [Print] England |
PMID | 12105772
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- mafosfamide
- Cyclophosphamide
|
Topics |
- Adolescent
- Adult
- Antineoplastic Agents
(therapeutic use, toxicity)
- Bone Marrow Purging
(methods)
- Bone Marrow Transplantation
(adverse effects, mortality)
- Cyclophosphamide
(analogs & derivatives, therapeutic use, toxicity)
- Female
- Humans
- Incidence
- Leukemia, Myeloid, Acute
(complications, mortality, therapy)
- Longitudinal Studies
- Male
- Middle Aged
- Myelodysplastic Syndromes
(etiology)
- Neoplasms, Second Primary
- Prognosis
- Survival Analysis
- Transplantation, Autologous
(adverse effects, mortality)
- Treatment Outcome
- Whole-Body Irradiation
|